AYTU BIOPHARMA, INC (AYTU) [Rocket]

Overview

AYTU BIOPHARMA, INC (AYTU)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/12/2023	10-K	Annual Report for the period ended June 30, 2023
10/06/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/03/2023	4	PYSZCZYMUKA GREG (Chief Commercial Officer) has filed a Form 4 on AYTU BIOPHARMA, INC
09/29/2023	NT 10-K	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
09/27/2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
08/18/2023	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/15/2023	4	Disbrow Jarrett (Chief Business Officer) has filed a Form 4 on AYTU BIOPHARMA, INC

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Jun-30-23	Jun-30-22	Jun-30-21	Jun-30-20	Jun-30-19	Jun-30-18	Jun-30-17	Jun-30-16
Revenues	107.4	96.7	65.6	27.6	7.3	3.7	3.2	2.6
Revenue growth	11.1%	47.3%	137.5%	277.5%	100.0%	13.6%	25.7%	878.8%
Cost of goods sold	40.8	44.4	36.4	8.3	2.2	2.1	1.4	1.0
Gross profit	66.6	52.3	29.2	19.4	5.1	1.6	1.8	1.6
Gross margin	62.0%	54.1%	44.5%	70.0%	69.9%	44.0%	56.0%	62.6%
Selling, general and administrative					18.9	17.7	17.4	8.5
Sales and marketing	41.4	38.7	30.3	11.4
Research and development	4.1	14.4	5.6	1.7	0.6	0.2	1.0
General and administrative	28.6	31.2	25.5	19.7
EBITA	-12.3	-32.0	-32.2	-13.4	-14.7	-13.7	-17.4	-13.5
EBITA margin	-11.4%	-33.1%	-49.1%	-48.6%	-201.0%	-375.3%	-539.0%	-528.4%
Amortization of intangibles	4.8	4.1	6.0	4.5	2.1	1.6	1.7	0.7
EBIT	-17.1	-36.1	-38.2	-17.9	-16.8	-15.3	-19.1	-14.2
EBIT margin	-15.9%	-37.3%	-58.3%	-64.9%	-230.1%	-417.8%	-592.0%	-554.3%
Pre-tax income	-17.1	-110.3	-58.0	-13.6	-27.1	-10.2	-22.5	-28.2
Income taxes	0.0	-0.1	0.3	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.1%		0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-17.1	-110.2	-58.3	-13.6	-27.1	-10.2	-22.5	-28.2
Net margin	-15.9%	-114.0%	-88.8%	-49.3%	-370.6%	-278.3%	-698.7%	-1099.7%

Diluted EPS	($5.11)	($3.75)	($3.48)	($3.01)	($3.48)	($15.31)	($48.30)
Shares outstanding (diluted)	3.3	29.4	16.7	4.5	7.8	0.7	0.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.